Press Releases

 
Press Releases
  Date Title and Summary View
Sep 13, 2017
HERTFORDSHIRE, England and PITTSBURGH, Sept. 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Dennis Zeleny as chief human relations officer. Zeleny joins Mylan with 30 years of experience leading global, corporate HR organizations and consulting on HR policy matters. ...
Aug 24, 2017
TOKYO, HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2017 /PRNewswire/ -- Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Mylan N.V. (NASDAQ, TASE: MYL) have entered into a license agreement between their respective subsidiaries, Otsuka Novel Products GmbH (ONPG) and Mylan Pharmaceuticals Private Limited (Mylan), to commercialize delamanid for the tr...
Aug 17, 2017
HERTFORDSHIRE, England and PITTSBURGH, Aug. 17, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its subsidiaries, Mylan Inc. and Mylan Specialty L.P., have signed an agreement with the U.S. Department of Justice ("DOJ") and two relators finalizing the Medicaid drug rebate settlement that the Company announced on Oct. 7, 201...
Aug 10, 2017
Mylan now offers generic alternatives to Truvada®, Atripla® and Viread® to patients in Canada1 HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017 /PRNewswire/ -- Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced the launch i...
Aug 9, 2017
HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and six months ended June 30, 2017. Second Quarter 2017 Financial Highlights Total revenues of $2.96 billion, up 16% compared to the pr...
Aug 8, 2017
HERTFORDSHIRE, England and PITTSBURGH, Aug. 8, 2017 /PRNewswire/ -- Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, has received marketing authorization from the Drug Controller General of India (DCGI) for its antiretroviral (ARV) drug Avonza™ (TLE400). AvonzaT...
Aug 7, 2017
HERTFORDSHIRE, England and PITTSBURGH, Aug. 7, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of tentative approval from the U.S. Food and Drug Administration under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Lamivu...
Jul 26, 2017
HERTFORDSHIRE, England and PITTSBURGH, July 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of approval from the World Health Organization Prequalification of Medicines Program (WHO PQ) of its application for Sofosbuvir Tablets, 400 mg, a generic version of Gilead Sciences' S...
Jul 19, 2017
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208), an investigational long-acting muscarinic antagonist (LAMA) an...
Jul 19, 2017
HERTFORDSHIRE, England and PITTSBURGH, July 19, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Wednesday, Aug. 9, 2017, at 10 a.m. ET, to review the company's financial results for the second quarter ended June 30, 2017. Mylan will release its financial results on Aug. 9,...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase